Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ataluren (PTC124) for nonsense-mutation cystic fibrosis
2008-003924-52Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ataluren in cystic fibrosis (CF), sponsored by PTC Therapeutics, Inc. Primary endpoint: Relative change in percent-predicted FEV1 from baseline to Week 48. Started Dec 2008; status: completed.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2008-003924-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003924-52.